PubRank

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Clinical Trial ID NCT01722487

PubWeight™ 43.64‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01722487

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013 16.33
2 Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014 6.73
3 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015 5.69
4 Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2013 4.19
5 Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015 3.47
6 Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013 1.07
7 Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol 2014 0.97
8 Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2013 0.92
9 Initial treatment of CLL: integrating biology and functional status. Blood 2015 0.90
10 How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 2014 0.90
11 Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol 2015 0.89
12 A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag 2015 0.87
13 Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol 2014 0.82
14 Novel Bruton's tyrosine kinase inhibitors currently in development. Onco Targets Ther 2013 0.80
15 Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol 2014 0.77
16 Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib. J Hematol Oncol 2015 0.77
Next 100